Current Diagnostics May Mischaracterize Tumors1-6

Actor portrayal

Image-based glioma management is complicated by treatment-related changes, which may resemble tumor progression and impact clinical decision-making1-6

18%-30%

pseudoprogression, which mimics tumor growth1-3

Up to

30%

radiation necrosis, which mimics tumor growth but is actually cell death due to treatment1,4-6

20%-60%

pseudoresponse, which mimics tumor shrinkage but is actually reduced contrast due to vascular changes5

18F-FET PET imaging: more than 20 years of European experience overcoming diagnostic limitations7

Supplementing MRI with 18F-FET PET offers a clear path forward.8-10

90% sensitivity and specificity when used with MRI8

Low background uptake in normal brain tissue9

Tumor-specific targeting9

Capable of distinguishing tumor recurrence from treatment-related change9

Long half-life9,10

41% higher diagnostic accuracy when combined with MRI vs MRI alone11

Pixclara® (18F-FET) PET demonstrated strong diagnostic performance across multiple studies.10

View Efficacy Data

18F-FET, 18F-fluoro-ethyl-tyrosine; MRI, magnetic resonance imaging; PET, positron emission tomography.